These results suggest that PGRMC1 attenuates the EGFR-TKI efficiency via activation of Wnt/β-catenin and NF-κB pathways in NSCLC and that PGRMC1 is a potential target molecular to overcome EGFR-TKI resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.